Health Economics›Malignant solid neoplasm EGFR-mutated›All lines of therapy

All lines of therapy

Malignant solid neoplasm EGFR-mutated · 1 regimen

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Erlotinib monotherapy Variant #01	EGFR	R 13 907	28d	~9.7 mo	~8.8 mo	~11	~R 152 976 PFS proxy · indirect	30

1 of 1 regimen shown